Recent studies showed that PPARγ was decreased in elderly AF patients [36] and hypertensive AF patients [37], while PPARγ agonists could inhibit atrial remodeling in AF models [38, 39] and prevent new onset AF in patients with non-insulin dependent diabetes [40]. The gene discussed is PPARG; the disease is atrial fibrillation.